These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 39308371)

  • 1. Interatrial Shunt Treatment for Heart Failure: The Randomized RELIEVE-HF Trial.
    Stone GW; Lindenfeld J; Rodés-Cabau J; Anker SD; Zile MR; Kar S; Holcomb R; Pfeiffer MP; Bayes-Genis A; Bax JJ; Bank AJ; Costanzo MR; Verheye S; Roguin A; Filippatos G; Núñez J; Lee EC; Laufer-Perl M; Moravsky G; Litwin SE; Prihadi E; Gada H; Chung ES; Price MJ; Thohan V; Schewel D; Kumar S; Kische S; Shah KS; Donovan DJ; Zhang Y; Eigler NL; Abraham WT;
    Circulation; 2024 Sep; ():. PubMed ID: 39308371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interatrial shunt therapy in advanced heart failure: Outcomes from the open-label cohort of the RELIEVE-HF trial.
    Rodés-Cabau J; Lindenfeld J; Abraham WT; Zile MR; Kar S; Bayés-Genís A; Eigler N; Holcomb R; Núñez J; Lee E; Perl ML; Moravsky G; Pfeiffer M; Boehmer J; Gorcsan J; Bax JJ; Anker S; Stone GW
    Eur J Heart Fail; 2024 Apr; 26(4):1078-1089. PubMed ID: 38561314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial.
    Shah SJ; Borlaug BA; Chung ES; Cutlip DE; Debonnaire P; Fail PS; Gao Q; Hasenfuß G; Kahwash R; Kaye DM; Litwin SE; Lurz P; Massaro JM; Mohan RC; Ricciardi MJ; Solomon SD; Sverdlov AL; Swarup V; van Veldhuisen DJ; Winkler S; Leon MB;
    Lancet; 2022 Mar; 399(10330):1130-1140. PubMed ID: 35120593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One-Year Safety and Clinical Outcomes of a Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction in the Reduce Elevated Left Atrial Pressure in Patients With Heart Failure (REDUCE LAP-HF I) Trial: A Randomized Clinical Trial.
    Shah SJ; Feldman T; Ricciardi MJ; Kahwash R; Lilly S; Litwin S; Nielsen CD; van der Harst P; Hoendermis E; Penicka M; Bartunek J; Fail PS; Kaye DM; Walton A; Petrie MC; Walker N; Basuray A; Yakubov S; Hummel SL; Chetcuti S; Forde-McLean R; Herrmann HC; Burkhoff D; Massaro JM; Cleland JGF; Mauri L
    JAMA Cardiol; 2018 Oct; 3(10):968-977. PubMed ID: 30167646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcatheter InterAtrial Shunt Device for the treatment of heart failure: Rationale and design of the pivotal randomized trial to REDUCE Elevated Left Atrial Pressure in Patients with Heart Failure II (REDUCE LAP-HF II).
    Berry N; Mauri L; Feldman T; Komtebedde J; van Veldhuisen DJ; Solomon SD; Massaro JM; Shah SJ
    Am Heart J; 2020 Aug; 226():222-231. PubMed ID: 32629295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure With Preserved Ejection Fraction (REDUCE LAP-HF I [Reduce Elevated Left Atrial Pressure in Patients With Heart Failure]): A Phase 2, Randomized, Sham-Controlled Trial.
    Feldman T; Mauri L; Kahwash R; Litwin S; Ricciardi MJ; van der Harst P; Penicka M; Fail PS; Kaye DM; Petrie MC; Basuray A; Hummel SL; Forde-McLean R; Nielsen CD; Lilly S; Massaro JM; Burkhoff D; Shah SJ;
    Circulation; 2018 Jan; 137(4):364-375. PubMed ID: 29142012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Torsemide Versus Furosemide After Discharge in Patients Hospitalized With Heart Failure Across the Spectrum of Ejection Fraction: Findings From TRANSFORM-HF.
    Kapelios CJ; Greene SJ; Mentz RJ; Ikeaba U; Wojdyla D; Anstrom KJ; Eisenstein EL; Pitt B; Velazquez EJ; Fang JC;
    Circ Heart Fail; 2024 Mar; 17(3):e011246. PubMed ID: 38436075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-Year Outcomes of an Atrial Shunt Device in HFpEF/HFmrEF: Results From REDUCE LAP-HF II.
    Gustafsson F; Petrie MC; Komtebedde J; Swarup V; Winkler S; Hasenfuß G; Borlaug BA; Mohan RC; Flaherty JD; Sverdlov AL; Fail PS; Chung ES; Lurz P; Lilly S; Kaye DM; Cleland JGF; Cikes M; Leon MB; Cutlip DE; van Veldhuisen DJ; Solomon SD; Shah SJ
    JACC Heart Fail; 2024 Aug; 12(8):1425-1438. PubMed ID: 38934964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Rhythm Control Therapy in Patients With Atrial Fibrillation and Heart Failure.
    Rillig A; Magnussen C; Ozga AK; Suling A; Brandes A; Breithardt G; Camm AJ; Crijns HJGM; Eckardt L; Elvan A; Goette A; Gulizia M; Haegeli L; Heidbuchel H; Kuck KH; Ng A; Szumowski L; van Gelder I; Wegscheider K; Kirchhof P
    Circulation; 2021 Sep; 144(11):845-858. PubMed ID: 34328366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No-Implant Interatrial Shunt for HFpEF: 6-Month Outcomes From Multicenter Pilot Feasibility Studies.
    Udelson JE; Barker CM; Wilkins G; Wilkins B; Gooley R; Lockwood S; Potter BJ; Meduri CU; Fail PS; Solet DJ; Feldt K; Kriegel JM; Shaburishvili T
    JACC Heart Fail; 2023 Aug; 11(8 Pt 2):1121-1130. PubMed ID: 37115132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-Year Outcomes After Transcatheter Insertion of an Interatrial Shunt Device for the Management of Heart Failure With Preserved Ejection Fraction.
    Kaye DM; Hasenfuß G; Neuzil P; Post MC; Doughty R; Trochu JN; Kolodziej A; Westenfeld R; Penicka M; Rosenberg M; Walton A; Muller D; Walters D; Hausleiter J; Raake P; Petrie MC; Bergmann M; Jondeau G; Feldman T; Veldhuisen DJ; Ponikowski P; Silvestry FE; Burkhoff D; Hayward C
    Circ Heart Fail; 2016 Dec; 9(12):e003662. PubMed ID: 27852653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction.
    Butler J; Filippatos G; Siddiqi TJ; Ferreira JP; Brueckmann M; Bocchi E; Böhm M; Chopra VK; Giannetti N; Iwata T; Januzzi JL; Kaul S; Piña IL; Ponikowski P; Rauch-Kröhnert U; Shah SJ; Senni M; Sumin M; Verma S; Zhang J; Pocock SJ; Zannad F; Packer M; Anker SD
    Circulation; 2022 Oct; 146(14):1046-1055. PubMed ID: 36098051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial.
    Butt JH; Docherty KF; Petrie MC; Schou M; Kosiborod MN; O'Meara E; Katova T; Ljungman CEA; Diez M; Ogunniyi MO; Langkilde AM; Sjöstrand M; Lindholm D; Bengtsson O; Martinez FA; Ponikowski P; Sabatine MS; Solomon SD; Jhund PS; McMurray JJV; Køber L
    JAMA Cardiol; 2021 Jun; 6(6):678-689. PubMed ID: 33787831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decongestion With Acetazolamide in Acute Decompensated Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction: A Prespecified Analysis From the ADVOR Trial.
    Martens P; Dauw J; Verbrugge FH; Nijst P; Meekers E; Augusto SN; Ter Maaten JM; Damman K; Mebazaa A; Filippatos G; Ruschitzka F; Tang WHW; Dupont M; Mullens W
    Circulation; 2023 Jan; 147(3):201-211. PubMed ID: 36335479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials.
    McMurray JJV; Docherty KF; de Boer RA; Hammarstedt A; Kitzman DW; Kosiborod MN; Maria Langkilde A; Reicher B; Senni M; Shah SJ; Wilderäng U; Verma S; Solomon SD
    Circulation; 2024 Mar; 149(11):825-838. PubMed ID: 38059368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial.
    Vaduganathan M; Claggett BL; Jhund P; de Boer RA; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Desai AS; Hegde SM; Lindholm D; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
    JAMA Cardiol; 2022 Dec; 7(12):1259-1263. PubMed ID: 36190011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure: Rationale and Design of the Randomized Trial to REDUCE Elevated Left Atrial Pressure in Heart Failure (REDUCE LAP-HF I).
    Feldman T; Komtebedde J; Burkhoff D; Massaro J; Maurer MS; Leon MB; Kaye D; Silvestry FE; Cleland JG; Kitzman D; Kubo SH; Van Veldhuisen DJ; Kleber F; Trochu JN; Auricchio A; Gustafsson F; Hasenfuβ G; Ponikowski P; Filippatos G; Mauri L; Shah SJ
    Circ Heart Fail; 2016 Jul; 9(7):. PubMed ID: 27330010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the PARAGON-HF Study Results Using Win Ratio.
    Yoon M; Kim W; Kook W; Park JJ; Greenberg B
    Circ Heart Fail; 2024 Sep; 17(9):e011860. PubMed ID: 39193709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction - Results from the EMPULSE trial.
    Tromp J; Kosiborod MN; Angermann CE; Collins SP; Teerlink JR; Ponikowski P; Biegus J; Ferreira JP; Nassif ME; Psotka MA; Brueckmann M; Blatchford JP; Steubl D; Voors AA
    Eur J Heart Fail; 2024 Apr; 26(4):963-970. PubMed ID: 38572654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial Invasive Versus Conservative Management of Stable Ischemic Heart Disease in Patients With a History of Heart Failure or Left Ventricular Dysfunction: Insights From the ISCHEMIA Trial.
    Lopes RD; Alexander KP; Stevens SR; Reynolds HR; Stone GW; Piña IL; Rockhold FW; Elghamaz A; Lopez-Sendon JL; Farsky PS; Chernyavskiy AM; Diaz A; Phaneuf D; De Belder MA; Ma YT; Guzman LA; Khouri M; Sionis A; Hausenloy DJ; Doerr R; Selvanayagam JB; Maggioni AP; Hochman JS; Maron DJ
    Circulation; 2020 Nov; 142(18):1725-1735. PubMed ID: 32862662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.